The CHRYSALIS Study: Phase 1 Clinical Trial Is Open for Enrollment
The CHRYSALIS Study is for adults with previously treated advanced non-small-cell lung cancer (NSCLC). The study is broken down into different parts and is specifically recruiting patients with NSCLC that have a documented primary MET Exon 14 skipping mutation. An investigational medication will be given to eligible participants to assess its the safety, tolerability, and anti-tumor activity.
You may be able to take part in the study if you:
Are 18 years or older
Have been diagnosed with metastatic or unresectable NSCLC with a documented primary MET Exon 14 skipping mutation
Must have received prior treatment or declined currently available treatment. There are no limits on lines of prior treatment nor on the type of prior treatment. Patients are eligible post- chemo and post-MET TKI(s).
Trial ID: NCT02609776
Condition: Non-Small Cell Lung Cancer Intervention: Parallel Assignment Study Type: Interventional
Study Phase: I
Study Sponsor: Janssen Research & Development, LLC Trial Start Date: May 24, 2016
Trial End Date: November 1, 2023
Participant Goal: 460
Age Group: 18+ years of age Gender: All